ABSTRACT
Inflammation has a contributive role in the development and progression of chronic obstructive pulmonary disease (COPD).The present study was designed to determine the level and the distribution of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in COPD compared with controls. Ninety patients with COPD presented to an outpatient hospital clinic and 50 controls who were selected among personals of the same hospital entered the study. Serum high sensitive CRP (hs-CRP) was measured by immunoturbidimetric method and the ESR by Westergren method. Receiver operating characteristic curve was applied to determine a cutoff point for differentiation of the COPD and control group. In statistical analysis, the patients and controls were compared regarding levels and distribution of hs-CRP and ESR. Mean age of patients and controls was 67 ± 11.6 and 51.3 ± 6.7 years, respectively (p = 0.001). Mean hs-CRP was significantly higher (4.76 ± 5.6 vs 1.72 ± 1.68 mg/L, p = 0.001) but mean ESR was nonsignificantly higher (9.1 ± 11.2 vs 7.2 ± 7.4 m/h, p = 0.95) in patients than control. Serum hs-CRP at 1.55 mg/L, differentiated patients and controls at sensitivity of 77.3 % and specificity of 60 %. Serum hs-CRP >3 mg/L was observed in 39 (44.3 %) patients and 9 (18 %) controls (p = 0.001) and >6 mg/L in 22 (25 %) patients and 2 (4 %) controls (p = 0.001).Serum hs-CRP was significantly correlated with ESR in patient but not in control group (Spearman correlation coefficient = 0.516, p = 0.001). Serum hs-CRP and ESR was not correlated with age, weigh, smoking, and the severity of COPD. The results of this study indicated a systemic inflammatory process in COPD. Since inflammation has an important contribution in development of future pulmonary and extrapulmonary complications, serum CRP assessment will provide additional information beyond that achieved by conventional method of pulmonary function test.
Similar content being viewed by others
REFERENCES
Chung, K.F., and I.M. Adcock. 2008. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31: 1334–56.
Wouters, E. 2009. COPD: from obstructive lung disease to chronic systemic inflammatory syndrome? Pneumologie 63: S107–12 [In German].
Sevenoaks, M.J., and R.A. Stockley. 2006. Chronic obstructive pulmonary disease, inflammation and co-morbidity—a common inflammatory phenotype? Respir Res 7: 70,1–9.
Fabbri, L.M., F. Luppi, B. Beghe, and K.F. Rabe. 2008. Complex chronic comorbidities of COPD. Eur Respir J 31: 204–12.
Oudijk, E.J., J.W. Lammers, and L. Koenderman. 2003. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J 46: 5s–13s.
Heidari, B., P. Heidari, and M.E. Tayebi. 2007. The value of changes in CRP and ESR for predicting treatment response in rheumatoid arthritis. APLAR J Rheumatol 10: 23–8.
Bedel, S.E., and B.T. Bush. 1985. Erythrocyte sedimentation rate from folklore to fact. Am J Med. 78: 1001–9.
Heidari, B. 2012. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. Caspian J Intern Med. 3: 428–435.
Tofan, F., M.H. Rahimi-Rad, Y. Rasmi, and S. Rahimirad. 2012. High sensitive C-reactive protein for prediction of adverse outcome in acute exacerbation of chronic obstructive pulmonary disease. Pneumologia. 61: 160–2.
Dahl, M., J. Vestbo, P. Lange, S.E. Bojesen, A. Tybjaerg-Hansen, and B.G. Nordestgaard. 2007. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 250–5.
Hurst, J.R., G.C. Donaldson, W.R. Perera, T.M. Wilkinson, J.A. Bilello, G.W. Hagan, R.S. Vessey, and J.A. Wedzicha. 2006. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174: 867–74.
Patel, A.R., J.R. Hurst, and J.A. Wedzicha. 2010. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 31: 267–75.
Sin, D.D., P. Lacy, E. York, and S.F. Man. 2004. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 760–5.
Man, S.F., J.E. Connett, N.R. Anthonisen, R.A. Wise, D.P. Tashkin, and D.D. Sin. 2006. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61: 849–53.
de Torres, J.P., V. Pinto-Plata, C. Casanova, H. Mullerova, E. Córdoba-Lanús, M. Muros de Fuentes, A. Aguirre-Jaime, and B.R. Celli. 2008. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133: 1336–43.
Zhang, Y.H., L.J. Guo, G. Kuang, M. Zhu, and L.R. Liang. 2010. Association between the erythrocyte sedimentation rate, serum C-reactive protein and risk of lung cancer. Zhonghua Zhong Liu Za Zhi 32: 48–51 [In Chinese].
Sin, D.D., and S.F. Man. 2003. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107(11): 1514–9.
Piehl-Aulin, K., I. Jones, B. Lindvall, A. Magnuson, and S.M. Abdel-Halim. 2009. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 78: 191–6.
Karadag, F., S. Kirdar, A.B. Karul, and E. Ceylan. 2008. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 19: 104–8.
Zhang, Y., H. Bunjhoo, W. Xiong, Y. Xu, and D. Yang. 2012. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Int Med Res. 40: 1629–35.
Thorleifsson, S.J., O.B. Margretardottir, G. Gudmundsson, I. Olafsson, B. Benediktsdottir, C. Janson, A.S. Buist, and T. Gislason. 2009. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med 103: 1548–53.
Valipour, A., M. Schreder, M. Wolzt, S. Saliba, S. Kapiotis, P. Eickhoff, and O.C. Burghuber. 2008. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 115: 225–32.
Saetta, M. 1999. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160: S17–20.
Gan, W.Q., S.F. Man, A. Senthilselvan, and D.D. Sin. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 59: 574–80.
Kushner, I. 1982. The phenomenon of the acute phase response. Ann N Y Acade Sci. 389: 39–48.
Osei-Bimpong, A., J.H. Meek, and S.M. Lewis. 2007 Aug. Hematology. 2007 Aug;12(4):353-7.ESR or CRP? A comparison of their clinical utility. Hematology 12(4): 353–7.
Pauwels, R.A., A.S. Buist, P. Ma, C.R. Jenkins, and S.S. Hurd. 2001. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46(8): 798–825. Review.
Pfützner, A., and T. Forst. 2006. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther. 8: 28–36.
Bircan, A., M. Gokirmak, O. Kilic, O. Ozturk, and A. Akkaya. 2008. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract 17: 202–8.
Corsonello, A., C. Pedone, S. Battaglia, G. Paglino, V. Bellia, and R. Incalzi. 2011. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr 53(2): 190–5. doi:10.1016/j.archger.2010.10.015. Epub 2010 Nov 12.
Feldman, M., B. Aziz, G.N. Kang, M.A. Opondo, R.K. Belz, and C. Sellers. 2013. C-reactive protein and erythrocyte sedimentation rate discordance: frequency and causes in adults. Transl Res 161(1): 37–43. doi:10.1016/j.trsl.2012.07.006. Epub 2012 Aug 23.
Garcia-Rio, F., M. Miravitlles, J.B. Soriano, L. Muñoz, E. Duran-Tauleria, G. Sánchez, V. Sobradillo, and J. Ancochea. 2010. EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 11: 63. doi:10.1186/1465-9921-11-63.
Kirdar, S., M. Serter, E. Ceylan, A.G. Sener, T. Kavak, and F. Karadağ. 2009. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 69(2): 219–24. doi:10.1080/00365510802474400.
Lazovic, B. 2012. Correlation of CRP and serum level of fibrinogen with severity of disease in chronic obstructive pulmonary disease patients. Med Arh 66(3): 159–60.
Peng, C., C. Tian, Y. Zhang, X. Yang, and Y. Feng. 2013 Mar. Fan H.C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 345(3): 190–4.
Acknowledgments
This study was funded by the Chancellor for Research and Technology, Babol University of Medical Sciences, Babol, Iran
Conflict of Interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Firouzjahi, A., Monadi, M., Karimpoor, F. et al. Serum C-reactive Protein Level and Distribution in Chronic Obstructive Pulmonary Disease Versus Healthy Controls: a Case–Control Study from Iran. Inflammation 36, 1122–1128 (2013). https://doi.org/10.1007/s10753-013-9646-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-013-9646-7